CMI Inc. and Life Molecular Imaging Announce the Reimbursement of the Amyloid-PET Diagnostic Neuraceq® (florbetaben 18F) in Japan

Posted on by

First Reimbursed Amyloid PET Diagnostic Tool in Japan TOKYO and BERLIN, Nov. 22, 2023 /PRNewswire/ — CMI Inc. and Life Molecular Imaging (LMI) are pleased to announce that the amyloid-PET diagnostic Neuraceq® (florbetaben 18F injection) has been approved from the Ministry of Health,…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.